Abiopharma

Johnson & Johnson - RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer

MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval

Eaton Vance Closed-End Funds Release Estimated Sources of Distributions

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer

Mynd.ai Regains Compliance with NYSE American Filing Requirements Following Submission of Annual Report on Form 20-F

Donaldson Company Increases Quarterly Cash Dividend 6.7%

UPWK Investors Have Opportunity to Join Upwork Inc. Fraud Investigation with the Schall Law Firm

ISS and Glass Lewis Support BIMIZCI’s Case for Change at Medallion Financial. Both Recommend Stockholders Vote on the BLUE Proxy Card FOR Election of Two BIMIZCI Nominees to Medallion Board

Sallie Mae Co-President and CFO to Speak at 2026 Morgan Stanley US Financials Conference